OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel
05 avr. 2022 07h30 HE
|
OpGen, Inc.
Interim analysis performed with initial 150 U.S. patient samples enrolled in its prospective multicenter trial for the Unyvero UTI panel - Clinical Trial to be continued without any...
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
29 mars 2022 16h05 HE
|
OpGen, Inc.
Total revenue for 2021 was approximately $4.3 millionStrong total cash position of approximately $36.1 million as of December 31, 2021, up significantly from $13.4 million at year-end 2020Conference...
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time
15 mars 2022 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter...
OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology
10 févr. 2022 16h30 HE
|
OpGen, Inc.
Publication demonstrates FDA cleared Acuitas AMR Gene Panel detects and differentiates a broad range of 28 AMR markers that can be associated with up to 9 antimicrobial classes Provides results at...
OpGen Announces Successful Completion of Unyvero A30 Development Milestone
10 févr. 2022 07h30 HE
|
OpGen, Inc.
Unyvero A30 RQ analyzer successfully completed verification and validation (V&V) testing as well as lifetime testingUnyvero A30 instruments met all V&V criteria for series-production systems ...
OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
18 janv. 2022 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update
10 janv. 2022 07h30 HE
|
OpGen, Inc.
Preliminary unaudited revenue for 2021 was approximately $4.3 millionMaintained strong balance sheet with $36.1 million cash as of December 31, 2021 and total capital raised in 2021 of $51.2...
OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents
14 déc. 2021 07h30 HE
|
OpGen, Inc.
Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical...
OpGen Announces Results of Special Meeting of Stockholders
08 déc. 2021 16h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction
30 nov. 2021 08h45 HE
|
OpGen, Inc.
Ares Genetic is granting a permanent, unrestricted and non-exclusive access to a small subset of the proprietary ARESdb data asset to an unnamed global corporation and leader in microbiology and...